20 (AIDX) Equity Average (2025 - 2026)
20 (AIDX) reported Equity Average of $1.3 million for Q1 2026, down 1.35% on a YoY basis from $1.3 million in Q1 2025, and up 142.77% quarter-over-quarter from $521834.0 in Q4 2025.
20 (AIDX) Equity Average (2025 - 2026) Analysis & Trends
20 has reported Equity Average for 2 years, with the latest figure at $1.3 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average fell 1.35% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 1.35% YoY), and the FY2025 full-year result was $743128.5, changed N/A from the prior year.
- Equity Average for Q1 2026 stood at $1.3 million, up from $521834.0 in the prior quarter.
- The five-year high for Equity Average was $1.3 million in Q1 2025, with the low at $521834.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 52.42 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 22.70 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 49.03 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 25.17 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 10.33 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 13.05 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 2.85 Bn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 10.53 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 7.18 Bn |
| 10 | 20 | - | - | 62,884.00 | 1.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.27 Mn |
| Dec 31, 2025 | 521,834.00 |
| Mar 31, 2025 | 1.28 Mn |